Table 3

Changes in histological grading of Helicobacter pylori infection before and after treatment

Eradication (Group HpE)*Placebo (Group Hp+)†p Value
All values are median (range).
*Within HpE group comparison between baseline and end of treatment: antral gastritis: p<0.0001, suggesting significant resolution of gastritis after H pylori eradication; corpus gastritis: p<0.0001, suggesting significant resolution of gastritis after H pylori eradication; antral atrophy: p = 0.07; corpus atrophy: p = 0.32; antral intestinal metaplasia: p = 0.11; corpus intestinal metaplasia: p = 1.0.
†Within Hp+ group comparison between baseline and end of treatment: antral gastritis: p = 0.15; corpus gastritis: p<0.0001, suggesting significant increase in severity of gastritis; antral atrophy: p = 0.28; corpus atrophy: 0.32; antral intestinal metaplasia: p = 0.053; corpus intestinal metaplasia: p = 0.32.
Antral gastritis
    Baseline4 (1–6)4 (1–6)0.28
    End of treatment1 (0–4)3 (1–6)<0.0001
Corpus gastritis
    Baseline3 (0–6)3 (0–6)0.56
    End of treatment1 (0–4)4 (0–6)<0.0001
Antral atrophy
    Baseline0 (0–2)0 (0–3)0.24
    End of treatment0 (0–3)0 (0–3)0.63
Corpus atrophy
    Baseline0 (0–1)0 (0–1)0.54
    End of treatment0 (0–1)0 (0–1)0.85
Antral intestinal metaplasia
    Baseline0 (0–2)0 (0–3)0.88
    End of treatment0 (0–3)0 (0–3)0.91
Corpus intestinal metaplasia
    Baseline0 (0–2)0 (0–1)0.18
    End of treatment0 (0–1)0 (0–1)0.45